Fractyl Health
- Country
- Ownership
- -
- Employees
- 102
- Market Cap
- -
- Introduction
Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.
Fractyl Health's Novel Smart GLP-1 Gene Therapy Shows Promise for Diabetes and Obesity Treatment
Fractyl Health's RJVA-001, a single-dose pancreatic gene therapy, demonstrated durable metabolic improvements in diabetic mouse models with significantly lower systemic GLP-1 exposure than conventional GLP-1 drugs.
Forge Biologics Partners with Fractyl Health to Manufacture AAV for Novel Pancreatic Gene Therapy Targeting Obesity and Type 2 Diabetes
Forge Biologics will provide AAV development and cGMP manufacturing services for Fractyl Health's Rejuva pancreatic gene therapy platform targeting obesity and type 2 diabetes.
WVU Medicine Leads Groundbreaking Trial of Endoscopic Procedure to Maintain GLP-1 Weight Loss
WVU Medicine is spearheading the REMAIN-1 clinical trial investigating Revita DMR, a minimally invasive procedure designed to maintain weight loss in patients discontinuing GLP-1 medications.
Fractyl Health's Revita Shows Promise in Maintaining Weight Loss After GLP-1 Discontinuation
Fractyl Health's REVEAL-1 study shows promising initial results for weight maintenance after discontinuing GLP-1 drugs using the Revita procedure.
Intensity Therapeutics and Fractyl Health Advance Clinical Programs in Oncology and Metabolic Disease
Intensity Therapeutics doses first patient in Phase 2 trial for triple-negative breast cancer and progresses Phase 3 sarcoma study.
Fractyl Health's Revita Shows Sustained Weight Loss and Improved Blood Sugar in Real-World Setting
Fractyl Health's Revita procedure demonstrated a nearly 13% total body weight loss at 12 months in patients with obesity and Type 2 Diabetes.
Fractyl Health's Revita System Receives FDA Breakthrough Device Designation for Weight Maintenance After GLP-1 Discontinuation
Fractyl Health's Revita System has been granted Breakthrough Device Designation by the FDA for weight maintenance after stopping GLP-1 drugs.